M. Hughes

Oncology · Journal of Clinical Oncology · 2006–2016

A researcher in the Science corpus: 15 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Oncology — 100 citations into it; #1,375 of 1,698 by trust here, #114 by citations
• Immunology — 81 citations into it; #1,742 of 2,160 by trust here, #302 by citations

Whom M. Hughes trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. S. Rosenberg

Who trusts M. Hughes overall

1. S. Rosenberg

Papers from M. Hughes's perspective

Ordered by how strongly the researchers M. Hughes trusts endorse each paper. Same corpus, a different order for every researcher.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
2. Final version of 2009 AJCC melanoma staging and classification. (Journal of Clinical Oncology)
3. Adoptive cell transfer: a clinical path to effective cancer immunotherapy (Nature Reviews. Cancer)
4. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma (New England Journal of Medicine)
5. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
6. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. (Journal of Clinical Oncology)
7. Categorical Data Analysis
8. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
9. Cancer immunotherapy: moving beyond current vaccines (Nature Medicine)
10. IL-2: The First Effective Immunotherapy for Human Cancer (Journal of Immunology)

Their papers

• Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy (2013) — 1,094 citations
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011) — 1,605 citations
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade (2007) — 631 citations
• Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma (2016) — 749 citations
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. (2015) — 1,473 citations
• A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response (2014) — 728 citations
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. (2012) — 1,404 citations
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy (2011) — 1,972 citations
• T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. (2011) — 813 citations
• Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma (2010) — 1,107 citations
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. (2009) — 1,438 citations
• Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens (2008) — 1,357 citations
• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (2007) — 703 citations
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. (2006) — 805 citations
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (2006) — 2,728 citations